The Emerald Tablets of Thoth the Atlantean Translation & Interpretation by Doreal (Originally published in mimeographed form in the 1930s by a mysterious "Dr. Doreal," these writings quickly became an ...

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s Disruptor 50 List.

NVO to Post New Semaglutide and CagriSema Results. Novo Nordisk’s semaglutide, a GLP-1 agonist, medicines gained significant traction, capturing a dominant share of the market.

Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: Real world evidence from an international retrospective cohort study. https://www ...

Semaglutide is marketed under the brand names Wegovy ® (semaglutide) injection 2.4 mg, Ozempic ® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, and Rybelsus ® (semaglutide) tablets 7 mg or 14 ...

Media: Ambre James-Brown +45 3079 9289... Liz Skrbkova (US) +1 609 917 0632... Investors: Jacob Martin Wiborg Rode +45 3075 5956... Ida Schaap Melvold ...

“Semaglutide has shown comprehensive and disease-modifying effects across the metabolic and cardiovascular health spectrum, and the data presented at ADA 2025 for Wegovy ®, Rybelsus ®, and Ozempic ® ...

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION per the EU drug regulator. Read more here.